Synonyms: Ivemend® | MK-0517
fosaprepitant is an approved drug (FDA and EMA (2008))
Compound class:
Synthetic organic
Comment: Marketed formulations contain fosaprepitant dimeglumine.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖![]() View more information in the IUPHAR Pharmacology Education Project: fosaprepitant |
|
No information available. |
Summary of Clinical Use ![]() |
Fosaprepitant is an intravenously administered prodrug of aprepitant, used to prevent nausea and vomiting induced by chemotherapy. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
The active metabolite of fosaprepitant, aprepitant, is a substance P analogue and acts as an antagonist of the neurokinin 1 receptor (NKR1). This prevents activation of NKR1 in the area of the medulla known as the vomiting center [2], and thereby reduces nausea and vomiting. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |